Bajaj Healthcare Ltd
Bajaj Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.
From Bajaj Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28.
- Peptide manufacturing plant (250 kg capacity) commissioning is targeted for Q4 FY27 with commercial revenue starting in 2028; expected peak revenue from this plant is INR 200-300 crores with EBITDA margins of 18%-20%.
- Oncology API facility is planned for commercialization by Q4 FY28.
- Expects near-term revenue from novel drugs such as Cenobamate (~INR 10-12 crores in FY27) and Suvorexant (commercialization by Q4 FY28).
- Longer-term top-line target is around INR 900-1000 crores within 2-3 years.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bajaj Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.
- Commissioning of a dedicated peptide manufacturing facility (capacity ~250 kg per annum) targeted by Q4 FY27.
- Construction of a dedicated oncology API manufacturing facility planned for commissioning by Q4 FY28.
- Expansion of DSIR-approved R&D centre at Savli into a large 10,000 sq ft facility expected operational by August 2026.
- Acquisition of GenRx Pharmaceutical manufacturing facility in Nashik, under NCLT approval, to strengthen formulation and oncology business.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bajaj Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Bajaj Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹153 Cr, net loss ₹23 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Bajaj Healthcare Ltd Q1 FY27 results?
Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.
What is Bajaj Healthcare Ltd share price analysis?
Bajaj Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 19.8 with a market cap of ₹1,113 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bajaj Healthcare Ltd planning capital expenditure?
Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.
Keep Bajaj Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.